Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JD023 in Relapsed/Refractory CD123+ AML
NCT05574608Phase 1Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JD023 in acute myeloid leukemia (AML), sponsored by Academy of Military Medical Sciences. Primary endpoints: Dose Limiting Toxicities at 1 month, Treatment-Emergent Adverse Events at 3 months and 1 more. Status: unknown.
02
Drugs
JD023
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05574608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574608.